Company Overview and News
Stop missing out on important events!
ImpediMed (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.
Updater Inc (ASX:IPD) has been granted a trading halt in its CHESS Depositary Interests by the ASX, with its shares placed in pre-open.
ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.
ImpediMed Ltd (ASX:IPD) is a leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies.
BRISBANE, Australia and CARLSBAD, Calif., July 18, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) announces that it is partnering with Vanderbilt University for a series of patient and clinician human factors testing for the company's next generation technology platform. Testing is expected to conclude by end of September 2016.
BRISBANE, Australia and CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the proposed outpatient payment rates for CY2017. This includes code 93702 for the company's L-Dex® procedure for the assessment of lymphedema.
CARLSBAD, Calif., March 22, 2016 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.